TNFRSF17 and plasma cell myeloma: Collectively, these findings identify TIGIT as a critical regulator of resistance to BCMA-CAR-T therapy and highlight TIGIT blockade as a promising strategy to enhance CAR-T efficacy and overcome relapse in multiple myeloma.